FORT LAUDERDALE, Fla., April 21, 2015 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the upcoming presentation of two abstracts supporting the ongoing clinical development of its OncAlert Oral Cancer Rapid Point-of-Care Risk Assessment Test and OncAlert Oral Cancer CD44 + Total Protein Lab Test at the American Association for Cancer Research (AACR) Annual Meeting 2015, taking place in Philadelphia, PA on April 18-22, 2015.
Details for the two poster presentations are as follows:
Wednesday, Apr 22, 2015 8:00 AM - 12:00 PM, location 40
Poster Session: LBPO.PR01. Late-Breaking Research: Prevention Research
- Abstract # LB-272 (Poster 10), "Effect of smoking cessation on soluble CD44 levels in head and neck cancer," Authors: Faisal F. Alotaibi, Turki M. Almuhaimid, Erika Reategui, Isildinha M. Reis, Claudia Gordon, Rohit Mathur, William Goodwin, Elizabeth J. Franzmann, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
- Abstract # LB-269 (Poster 7), "Nutritional effect on CD44 in head and neck cancer," Authors: Turki M. Almuhaimid, Erika P. Reategui, Faisal Alotaibi, Gordon Claudia, Isildinha M. Reis, W. Jarrad Goodwin and Elizabeth J. Franzmann, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
The meeting abstracts can be viewed online through the AACR website at www.aacr.org.
About the OncAlert Oral Cancer Risk Assessment System
Vigilant's initial product, the OncAlert Oral Cancer Risk Assessment System, includes the OncAlert Oral Cancer Rapid Point-of-Care Risk Assessment Test and the OncAlert Oral Cancer CD44 + Total Protein Lab Test. Both products in the OncAlert System are based on patented technology that detects specific protein markers known to indicate an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The test can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume alcohol, and people with human papillomavirus (HPV)). Both the rapid point-of-care test and the lab assay that comprise the OncAlert Oral Cancer Risk Assessment System are currently under the CE Mark registration approval process and expected for release in Q2 2015.
About Oral Cancer
According to the World Health Organization, there are over 600,000 new cases of head and neck cancer and 300,000 deaths each year worldwide. In the United States, more than 54,000 individuals were diagnosed with head and neck cancers in 2014, with 13,500 deaths from the disease. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Its point-of-care and lab-based products are accurate, effective and affordable, empowering healthcare practitioners to easily assess the risk of oral cancer early, and improve outcomes through earlier intervention. Vigilant Biosciences' OncAlert Oral Cancer Risk Assessment System's point-of-care and lab assay products are both currently undergoing the CE Mark registration approval process. For more information, visit www.vigilantbiosciences.com.
SOURCE Vigilant Biosciences, Inc.